iTeos Therapeutics (ITOS)
(Delayed Data from NSDQ)
$16.16 USD
-0.05 (-0.31%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $16.15 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for iTeos Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 13 | 268 | 345 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 13 | 268 | 345 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 164 | 141 | 100 | 45 | 28 |
Income After Depreciation & Amortization | -151 | 126 | 245 | -45 | -28 |
Non-Operating Income | 42 | 22 | 12 | 7 | 6 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -109 | 149 | 256 | -38 | -22 |
Income Taxes | 4 | 52 | 42 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -113 | 97 | 215 | -38 | -22 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -113 | 97 | 215 | -38 | -22 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -160 | 125 | 246 | -45 | -27 |
Depreciation & Amortization (Cash Flow) | -9 | -1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -151 | 126 | 245 | -45 | -28 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 35.76 | 37.77 | 37.78 | 15.08 | NA |
Diluted EPS Before Non-Recurring Items | -3.15 | 2.56 | 5.68 | -2.88 | NA |
Diluted Net EPS (GAAP) | -3.15 | 2.56 | 5.68 | -2.88 | -130.85 |
Fiscal Year end for iTeos Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 47.23 | 40.27 | 43.28 | 42.63 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -47.23 | -40.27 | -43.28 | -42.63 |
Non-Operating Income | NA | 11.23 | 12.08 | 9.86 | 9.55 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -36.00 | -28.19 | -33.42 | -33.07 |
Income Taxes | NA | 2.21 | 2.36 | -1.18 | 1.23 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -38.22 | -30.55 | -32.24 | -34.30 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -38.22 | -30.55 | -32.24 | -34.30 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 35.84 | 35.76 | 35.78 | 35.77 |
Diluted EPS Before Non-Recurring Items | NA | -1.07 | -0.85 | -0.90 | -0.96 |
Diluted Net EPS (GAAP) | NA | -1.07 | -0.85 | -0.90 | -0.96 |